INTRODUCTION
============

Glutamate is a major excitatory neurotransmitter in the central nervous system, and excessive activation of glutamate receptors can damage neurons via excitotoxicity. There are several lines of evidence that excitotoxicity plays a role in selective motor neuron death in amyotrophic lateral sclerosis (ALS).[@B1]-[@B3] Elevation of the extracellular glutamate level causes degeneration of motor neurons through excessive stimulation of glutamate receptors. Both *N*-methyl-D-aspartate (NMDA) and α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors are responsible for excitotoxicity in motor neurons.[@B4],[@B5] This has led to several antiglutamate drugs being tested on patients with ALS,[@B6] of which riluzole has a modest effect on survival and is the only such drug approved by the US Food and Drug Adminstration for ALS.[@B7],[@B8]

Riluzole inhibits glutamate release by inactivating voltage-dependent sodium channels and a G-protein-dependent signal transduction process at glutamatergic nerve terminals.[@B9] Because NMDA receptors play crucial roles in various forms of synaptic plasticity, which is required in several normal processes such as learning and memory,[@B10],[@B11] drugs such as riluzole that completely block NMDA receptors would inevitably impair normal synaptic transmission and thereby cause numerous unwanted side effects. Such side effects could be avoided by producing a partial rather than a complete blockade of NMDA receptors.

Memantine is a low-affinity, noncompetitive open-channel receptor blocker with a rapid off-rate from the channel, permitting the blockade of excessive NMDA receptor activity without disrupting normal synaptic transmission.[@B12],[@B13] Neuroprotective properties of memantine have been shown in various *in vitro* and *in vivo* models of excitotoxicity,[@B14],[@B15] and it has been used clinically with excellent safety in various neurodegenerative disorders including Alzheimer\'s disease.[@B16],[@B17] In a recent study, memantine significantly delayed disease progress and increased the life span by about 1 week in a transgenic ALS mouse model carrying the G93A mutant of the human Cu-Zn superoxide dismutase (SOD) gene,[@B18] with immunohistochemistry revealing the expression of NMDA receptor subunits within neurons of varying sizes in both dorsal and ventral areas of the spinal cord, including motor neurons.[@B18] However, the starting point and delivery method of memantine treatment employed in that study are unfortunately not readily applicable in clinical treatments of patients with ALS.

In the present study, we attempted to determine the effect of oral administration of memantine given at the time of symptom onset on behaviors and survival of transgenic SOD1 mutant ALS mice.

MATERIALS AND METHODS
=====================

1. Animals and memantine treatment
----------------------------------

Transgenic mice overexpressing human SOD1 with a Gly-to-Ala mutation at position 93 were purchased from Jackson Laboratory (Bar Harbor, ME, USA) and maintained as hemizygotes by breeding transgenic males with wild-type B6SJL females. The transgenic progeny were genotyped for expression of the transgene by the polymerase chain reaction using primers specific for human SOD1. Throughout the experiments, animals were housed in a controlled environment (temperature of 20-22℃, humidity of 40-60%, and lights on from 0700 to 1900 hours) with free access to food and water. The animals were randomly divided into control, low-dose memantine (30 mg/kg/day), and high-dose memantine (90 mg/kg/day) groups, with 10 animals in each group. The transgenic mice were treated daily with memantine in the drinking water, beginning at 75 days of age. The daily dosage was calculated based on a daily water intake of 17.7 ml/100g/day.[@B19] Fresh solutions were prepared weekly.

2. Behavioral analysis
----------------------

Motor performance was evaluated twice weekly by a rotarod test (Columbus Instruments, OH, USA), paw grip endurance (PaGE), and an extension reflex of hindlimbs, beginning at 10 weeks of age after a 2-week learning period. The time period that mice remained on a rotarod rotating at a constant speed of 16 rpm was measured, with 300 s chosen as the arbitrarycut-off time. Animals performed three trials for each evaluation, and the longest duration achieved was recorded. PaGE was used to quantify the grip strength of the mouse. The wire lid was gently shaken to prompt the mouse to hold onto the grid before the lid was flipped upside down. The time before the mouse let go of the grid with at least both hindlimbs was measured. Each mouse was allowed three attempts to hold onto the inverted lid for an arbitrary maximum of 200 s, and the longest duration was recorded. The extension reflex was quantified using the following 4-point scoring system: 0 for loss of reflex, with hindlimbs and paws held close to the body; 1 for loss of reflex with marked flexion of the hindlimbs; 2 for hindlimbs extending to \<90 degrees with a decreased extension reflex in bilateral hindlimbs; 3 for hindlimbs extending to \<90 degrees with decreased extension reflex in unilateral hindlimbs; and 4 for hindlimbs reflexly extending to form an angle of approximately 120 degrees. The body weight of the mice was measured twice weekly.

The day of death was defined as when a mouse could no longer roll over within 30 s after being placed on its side on a flat surface.

3. Statistical analysis
-----------------------

All statistical analyses were performed using SPSS 12.0 for Windows software. Analysis of variance was used to analyze the significance of differences in behavioral performance and body weight. The Kaplan-Meier method was used to assess survival data. Statistical significance was accepted at the *p*\<0.05 level.

RESULTS
=======

The onset of disease in G93A transgenic mice was defined as the first day on which hindlimb weakness appeared, including tremor or altered splay reflex. Memantine was administered orally at the end of 11 weeks of age (75 days of age) when the mice showed the initial clinical signs.

Low- and high-dose memantine treatments tended to delay disease progression as assessed by behavioral performances, but the protective effect of memantine was not statistically significant compared with control (values in the control, low-dose memantine, and high-dose memantine groups: 112, 116, and 119 days on the rotarod, and 91, 102, and 112 days on the extension reflex, respectively) ([Fig. 1](#F1){ref-type="fig"}). In addition, no statistically significant difference was observed between the two memantine-treated groups, although further motor deterioration in the rotarod test and extension reflex tended to be delayed in the high-dose memantine group relative to the low-dose memantine group. Memantine treatment did not show any protective effect on the body weight or PaGE. However, low-dose memantine significantly prolonged the survival of the animals relative to control and high-dose memantine treatment: the median survival was 141 days in the low-dose memantine group but 135.5 and 134 days in the high-dose memantine and control groups, respectively (*p*\<0.05, see [Fig. 2](#F2){ref-type="fig"}).

No significant adverse effects associated with memantine treatment were observed.

DISCUSSION
==========

NMDA-receptor-mediated neurotoxicity has been implicated in a broad spectrum of neurological disorders, including ALS. The current data show that memantine (an NMDA receptor antagonist) prolongs the survival of G93A transgenic ALS mice by about 1 week (\~5% of the life span). Although we observed some tendencies, we found that memantine had no significant protective effect on motor deterioration. These results are similar to the effects of riluzole found in two human clinical trials,[@B7],[@B8] as well as in an animal study.[@B20] Riluzole exhibits a variety of pharmacologic actions, including inhibition of glutamate release from presynaptic nerve terminals,[@B21] modulation of both NMDA[@B22] and AMPA receptors,[@B23] and inhibition of high-affinity uptake of γ-aminobutyric acid.[@B24] Such diverse and nonspecific actions of riluzole would inevitably cause a variety of intolerable adverse effects. For this reason, an antiexcitotoxic therapy should act specifically and must block excessive activation of the relevant receptors, leaving normal function relatively intact in order to avoid side effects.

Memantine is a specific, noncompetitive open-channel NMDA receptor blocker with a rapid off-rate from the channel, permitting the preferential blockade of excessive NMDA receptor activity without disrupting normal activity.[@B12],[@B13] Many neurodegenerative diseases - including Alzheimer\'s disease, Parkinson\'s disease, Huntington\'s disease, and ALS . have a final common pathway of neuronal injury as a result of glutamate receptor overstimulation, especially of the NMDA subtype.[@B25] Therefore, memantine might be a good candidate treatment for alleviating excitotoxicity associated with several neurodegenerative diseases. In fact, memantine has been used clinically for over 20 years to treat Parkinson\'s disease, vascular dementia, and Alzheimer\'s disease. Moreover, the long-term safety and efficacy of memantine has been confirmed in the treatment of patients with moderate-to-severe Alzheimer disease.[@B26]

Many *in vitro* and *in vivo* studies have demonstrated the antiexcitotoxic effects of memantine in several neurodegenerative diseases, but there have been surprisingly few attempts to determine its effects on ALS. To our knowledge only one recent study[@B18] has investigated this, and concluded that the neuroprotective effect of memantine in a transgenic ALS mouse model carrying a high copy number of SOD1 (G93A) was probably due to the inhibition of spinal cord NMDA receptors, and suggested that memantine could be used in ALS patients to prolong survival. Despite these promising results, that study had limitations: (1) the memantine treatment began before the onset of symptoms due to there being no reliable diagnostic biomarkers for human ALS,[@B27] and (2) the delivery method was a subcutaneous injection, which is not readily applicable to patients with ALS.

In the present study, we demonstrated that the administration of memantine even at symptom onset (75 days of age) had therapeutic effects in ALS. Although the earliest deficits in motor power and coordination in SOD1 (G93A) transgenic mice are observed as early as 8 weeks of age, the designated onset time may differ with the test used for motor assessment.[@B28] The first clinical signs in the mice used in this study appeared at about 11 weeks of age, with the mice showing tremor, impairment of the hindlimb extension reflex, and reduced running time on the rotarod apparatus. While memantine significantly prolonged survival, no significant beneficial effects on motor performance, hindlimb extension reflex, or weight were detected. Such partial effects might be attributable to the delay in memantine treatment, or to motor neuron degeneration in ALS mice not being mediated via activation of NMDA receptors alone, since there is evidence that AMPA/kainate receptors play a major role in neurotoxicity.[@B29] In this regard, a previous experimental study has demonstrated that an AMPA/kainate receptor antagonist significantly protected against the calcium influx and neurotoxicity, while an NMDA receptor antagonist had only a mild effect.[@B30] Moreover, Tortarolo et al. demonstrated that a new noncompetitive AMPA antagonist partially protected motor neurons, improved motor function, and prolonged the survival of SOD1 (G93A) transgenic ALS mice.[@B31]

Memantine exerted a dose-dependent protective effect on motor deterioration but not on survival. This discrepancy might be due to erratic ingestion of the water containing memantine. We did not estimate the plasma concentration of memantine. The therapeutic plasma concentration of memantine for Alzheimer\'s disease is approximately 1 µM.[@B32] The steady-state plasma levels following oral administration of 10, 30, and 100 mg/kg/day memantine were reportedly 0.49±0.06, 1.14±0.07, and 5.54±0.4 µM (mean±SD), respectively, in male C56BL/6J mice.[@B33] Based on these data, a dose of 30 mg/kg/day should produce the therapeutic plasma level of 1 µM in Alzheimer\'s disease. Additional work is needed to explore whether a serum level of 1 µM is also effective in ALS.

In conclusion, we have confirmed that memantine prolongs the survival of and delays motor deterioration in SOD1 (G93A) transgenic ALS mice. These results combined with those from a previous memantine study for ALS[@B18] suggest that memantine could be used as a new and effective NMDA receptor antagonist to manage human ALS patients with acceptable long-term safety and tolerability. The next steps are to determine whether memantine is also effective in human ALS and whether a combination therapy with other agents exerts better therapeutic effects than memantine treatment alone.
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